Your browser doesn't support javascript.
Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective.
Flaherty, Keith T; Doroshow, James H; Galbraith, Susan; Ribas, Antoni; Kluetz, Paul G; Pazdur, Richard; Theoret, Marc R.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. kflaherty@mgh.harvard.edu.
  • Doroshow JH; NCI, NIH, Bethesda, Maryland.
  • Galbraith S; AstraZeneca, Los Angeles, California.
  • Ribas A; Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA), Los Angeles, California.
  • Kluetz PG; Oncology Center of Excellence, Food and Drug Administration, Silver Spring, Maryland.
  • Pazdur R; Oncology Center of Excellence, Food and Drug Administration, Silver Spring, Maryland.
  • Theoret MR; Oncology Center of Excellence, Food and Drug Administration, Silver Spring, Maryland.
Cancer Discov ; 11(8): 1881-1885, 2021 08.
Article in English | MEDLINE | ID: covidwho-1320457

Full text: Available Collection: International databases Database: MEDLINE Main subject: Clinical Trials as Topic / COVID-19 / Neoplasms Type of study: Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Cancer Discov Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Clinical Trials as Topic / COVID-19 / Neoplasms Type of study: Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Cancer Discov Year: 2021 Document Type: Article